| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Provectus Biopharmaceuticals, Inc.
13D
PVCT · 74373P108
|
5.7% |
12/8/2025
Event 12/2/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.